期刊
ANNUAL REVIEW OF MEDICINE, VOL 70
卷 70, 期 -, 页码 121-135出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-040717-051127
关键词
Zika virus; ZIKV; dengue virus; flavivirus; vaccine; antibody; neutralization; antibody-dependent enhancement
资金
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001209, ZIAAI005047] Funding Source: NIH RePORTER
- NIAID NIH HHS [U19 AI083019, R01 AI104972, R01 AI073755] Funding Source: Medline
- NICHD NIH HHS [R01 HD091218] Funding Source: Medline
Zika virus (ZIKV) emerged at a global level when it spread to the Americas and began causing congenital malformations and microcephaly in 2015. A rapid response by academia, government, public health infrastructure, and industry has enabled the expedited development and testing of a suite of vaccine platforms aiming to control and eliminate ZIKV-induced disease. Analysis of key immunization and pathogenesis studies in multiple animal models, including during pregnancy, has begun to define immune correlates of protection. Nonetheless, the deployment of ZIKV vaccines, along with the confirmation of their safety and efficacy, still has major challenges, one of which is related to the waning of the epidemic. In this review, we discuss the measures that enabled rapid progress and highlight the path forward for successful deployment of ZIKV vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据